Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $513 | In Stock | |
10 mg | $826 | In Stock | |
25 mg | $1,260 | In Stock | |
50 mg | $1,680 | In Stock | |
100 mg | $2,290 | In Stock |
Description | Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis. |
In vitro | Derived from the mouse anti-human mAb HB12b, Inebilizumab had already shown impressive activity in depleting B cells in transgenic mice carrying the human CD19 gene (hCD19 Tg)[1]. Inebilizumab potently depletes CD19-expressing B cells, including primary human B cells, B cell lines derived from multiple tumor types, and neoplastic B cells[1]. Inebilizumab demonstrates equal or better activity than Rituximab in depleting human primary B cells in autologous ADCC assays and shows potent ADCC activity against human in vitro-differentiated and primary plasma cells[1]. |
In vivo | In vivo, Inebilizumab (MEDI-551) (i.v.; once; 0-10 mg/kg) depletes B cells from blood and spleen by mouse macrophages, and it induces phagocytosis of murine B cells ex vivo[2]. |
Alias | MEDI 551, MT-0551, 16C4-aFuc, VIB-0551 |
Cas No. | 1299440-37-1 |
Storage | store at low temperature store at -20°C |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.